User contributions
From Phaserwiki
(newest | oldest) View (newer 20 | older 20) (20 | 50 | 100 | 250 | 500)
- 09:46, 10 September 2009 (diff | hist) . . (+8) . . m Help:Contents (→Editing)
- 09:46, 10 September 2009 (diff | hist) . . (+10) . . m Help:Contents
- 09:44, 10 September 2009 (diff | hist) . . (-1) . . m Releases (→2003)
- 15:02, 8 September 2009 (diff | hist) . . (+490) . . m Keywords (→link=ENSEMBLE: add CARD)
- 12:16, 8 September 2009 (diff | hist) . . (+4) . . m Airlie J. McCoy
- 12:09, 8 September 2009 (diff | hist) . . (+12) . . Airlie J. McCoy
- 12:07, 8 September 2009 (diff | hist) . . (+4) . . Airlie J. McCoy
- 11:25, 8 September 2009 (diff | hist) . . (+1,065) . . Airlie J. McCoy
- 11:05, 8 September 2009 (diff | hist) . . (-43) . . m Airlie J. McCoy (Reverted edits by Airlie (Talk) to last version by WikiSysop)
- 11:04, 8 September 2009 (diff | hist) . . (+43) . . Airlie J. McCoy (Undo revision 459 by WikiSysop (Talk))
- 10:05, 8 September 2009 (diff | hist) . . (+1) . . Keywords (→link=MACHL)
- 09:58, 8 September 2009 (diff | hist) . . (+383) . . Keywords (→link=MACMR: add MACN)
- 09:56, 8 September 2009 (diff | hist) . . (+25) . . m Keywords (→link=TNCS)
- 09:55, 8 September 2009 (diff | hist) . . (+19) . . m Keywords (→link=TNCS)
- 15:22, 20 August 2009 (diff | hist) . . (-1) . . m Keywords (→link=VERBOSE)
- 15:21, 20 August 2009 (diff | hist) . . (+1) . . m Keywords (→link=VARSAD)
- 16:51, 11 July 2009 (diff | hist) . . (+7) . . N User Stories:V-kappa antibody fibre (Created page with 'testing') (current)
- 10:57, 9 July 2009 (diff | hist) . . (+1,435) . . N User Stories:ROP four-helix bundle (Initialize from paper)
- 17:39, 8 July 2009 (diff | hist) . . (+2,111) . . N User Stories:BETA-BLIP (Created page with 'The case of β-lactamase (BETA)–β- lactamase inhibitor (BLIP) has been used repeatedly as a test case for Phaser (Storoni et al., 2004; McCoy et al., 2005) because the origina...')
- 12:44, 2 July 2009 (diff | hist) . . (+6) . . m Contact
(newest | oldest) View (newer 20 | older 20) (20 | 50 | 100 | 250 | 500)